A team of scientists led by molecular biologist Rodrigo Moura Neto from the Federal University of Rio de Janeiro has made an exciting discovery in the world of cannabis research. The team found that a common Brazilian plant, known as Trema micrantha blume, contains cannabidiol (CBD), a compound that is increasingly being used to treat various conditions such as epilepsy, chronic pain, and anxiety.
The discovery presents a legal alternative to using cannabis, as Trema is abundant in Brazil and could be a simpler and cheaper source of cannabidiol. This finding is particularly significant for those who are looking for an alternative to traditional forms of medical marijuana.
CBD is one of the main active compounds in cannabis, alongside tetrahydrocannabinol (THC), which is responsible for the “high” feeling in users. While CBD has shown promise as a medical treatment, its effectiveness is still being researched. However, its popularity continues to grow due to its non-psychoactive properties and potential benefits for mental health.
Neto’s team plans to scale up their study to determine the best methods for extracting CBD from Trema and to analyze its effectiveness in patients who currently use medical cannabis. They have secured funding from the Brazilian government and estimate that the research will take at least five years to complete.
The global market for CBD is expanding rapidly, driven mainly by health and wellness use. A study by Vantage Market Research projected that the market for CBD would grow from nearly US$5 billion in 2022 to over US$47 billion by 2028. This discovery could have significant implications for the future of CBD production and availability. With this newfound source of CBD, it may become even easier for people around the world to access this popular substance that offers so many potential benefits.
In conclusion, this discovery marks an exciting new chapter in the world of cannabis research
